Covered recipient · General Payments record
XYLINA T GREGG
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$32,039.46
- Reported across 219 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,841.29 | 65 |
| Honoraria | $1,650.00 | 3 |
| Consulting Fee | $1,198.75 | 1 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Cornerstone Specialty Network LLC | $1,650.00 | 3 |
| Daiichi Sankyo Inc. | $1,384.96 | 14 |
| Karyopharm Therapeutics Inc. | $253.00 | 3 |
| Gilead Sciences, Inc. | $184.05 | 5 |
| GENZYME CORPORATION | $174.30 | 4 |
| PharmaEssentia USA Corporation | $133.00 | 1 |
| Merck Sharp & Dohme Corporation | $132.92 | 7 |
| Acerta Pharma LLC | $132.45 | 7 |
| SOBI, INC | $125.00 | 1 |
| Incyte Corporation | $117.71 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $107.33 | 4 |
| Genmab U.S., Inc. | $51.11 | 2 |
| Stemline Therapeutics Inc. | $48.69 | 2 |
| E.R. Squibb & Sons, L.L.C. | $44.56 | 2 |
| BeiGene USA, Inc. | $32.04 | 1 |
| PFIZER INC. | $24.48 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.42 | 1 |
| Rigel Pharmaceuticals, Inc. | $21.27 | 1 |
| Deciphera Pharmaceuticals Inc. | $20.08 | 1 |
| Astellas Pharma US Inc | $17.95 | 1 |
| Celgene Corporation | $17.91 | 1 |
| EISAI INC. | $17.58 | 1 |
| Immunocore Limited | $15.84 | 1 |
| Tempus AI, Inc | $15.59 | 1 |
| Agios Pharmaceuticals, Inc. | $14.93 | 1 |
| Janssen Biotech, Inc. | $14.55 | 1 |
| Lilly USA, LLC | $14.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (70)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.